Alpha Cognition Inc. has seen a notable increase in its stock holdings by Opaleye Management Inc., as reported in a recent SEC filing. This development is significant as it underscores the growing interest in Alpha Cognition's business and its potential in the biological products sector.
Background
Alpha Cognition Inc. operates in the biological products industry, specifically classified under SIC 2836, which focuses on biological products (no diagnostic substances). The company trades under the ticker ACOG on the Nasdaq exchange. It is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company. Recent filings include several Form 4 submissions, indicating active trading and ownership changes.
What the Filing Says
The latest filing, dated October 26, 2026, reveals that Opaleye Management Inc. has acquired additional shares of Alpha Cognition. On October 22, 2026, Opaleye purchased 17,117 shares at a weighted average price of $8.3266, increasing its total ownership to 3,277,011 shares. Following another transaction on October 23, 2026, where 14,973 shares were bought at a weighted average price of $8.2344, Opaleye's holdings grew to 3,291,984 shares.
Impact
This increase in share ownership by Opaleye Management, which is now a ten percent owner of Alpha Cognition, may influence the company's strategic direction and market positioning. The filing notes that Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by Opaleye, L.P., reflecting its significant role as an investment manager. This could lead to greater scrutiny and potential changes in Alpha Cognition's operations or strategy.
What's Next
Details were not available in the SEC filing regarding future actions or plans following this increase in ownership. However, the active trading and investment activity suggest ongoing interest in Alpha Cognition's developments and performance.